Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | STAT3 | P40763 | 1/20 | 0.62 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.58 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124113 | 0.85 | PARP1 (0.54) | MAPTCYP1A2CYP2C19NAMPTJAK2 | |
| SCHEMBL2169030 | 0.79 | MAPT (0.78) | SMN1; SMN2MAPTCYP1A2LMNACYP2C19 | |
| SCHEMBL1124148 | 0.76 | TGM2 (0.55) | SMN1; SMN2CYP2C19RAB9ANPC1L3MBTL1 | |
| SCHEMBL12078211 | 0.75 | ALDH1A1 (0.62) | SMN1; SMN2MAPTCYP1A2LMNACYP2C19 | |
| SCHEMBL4737529 | 0.74 | KCNQ3 (0.73) | SMN1; SMN2MAPTCYP1A2LMNACYP2C19 | |
| SCHEMBL213940 | 0.74 | HDAC1 (0.73) | SMN1; SMN2MAPTCYP1A2LMNACYP2C19 | |
| SCHEMBL8769978 | 0.74 | MAPT (0.70) | SMN1; SMN2MAPTCYP1A2LMNACYP2C19 | |
| SCHEMBL22495388 | 0.73 | MAPT (0.69) | SMN1; SMN2MAPTCYP1A2LMNACYP2C19 | |
| SCHEMBL31504224 | 0.73 | MAPT (0.69) | SMN1; SMN2MAPTCYP1A2LMNACYP2C19 | |
| SCHEMBL4251030 | 0.72 | MAPT (0.86) | SMN1; SMN2MAPTCYP1A2LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| WO-2019183600-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | SMN1; SMN2 3721/4885MAPT 442/4885CYP1A2 4418/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | SMN1; SMN2 1834/4885MAPT 961/4885CYP1A2 3732/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | SMN1; SMN2 3721/4885MAPT 442/4885CYP1A2 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.